Key facts
- Alebund Pharmaceuticals’s last known valuation is $530.5M (Oct 2025).
- It has raised $269.8M; the latest was IPO in Oct 2025.
- Notable investors include GIC Private, 5Y Capital, YuanBio Venture Capital, Tencent Investment, Morningside Group — 25 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Alebund Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Alebund Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alebund Pharmaceuticals
Operator of a biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. The company engages in the research, development, regulatory and commercialization of renal medicines, and has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease, thereby providing high-quality comprehensive solutions to the renal disease patients for the long-term.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 155
- Website
- alebund.com/
- Ownership
- In IPO Registration
Alebund Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alebund Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alebund Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.